China’s Bio-Thera Solutions and Russia’s Pharmapark have struck a deal to expand their existing biosimilars collaboration for Russia and the Commonwealth of Independent States with a further candidate: the Chinese firm’s BAT2306 proposed secukinumab biosimilar to Cosentyx.
China’s Bio-Thera Solutions and Russia’s Pharmapark have added the Chinese firm’s BAT2306 proposed rival to Cosentyx (secukinumab) to an existing biosimilars licensing and supply agreement covering Russia and the Commonwealth of Independent States.
Under the terms of the new deal, Pharmapark will have exclusive rights to distribute and market the secukinumab biosimilar “with...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
